AI assistant
Abliva — Share Issue/Capital Change 2016
May 31, 2016
3131_rns_2016-05-31_96189ad3-57fb-44d7-be2c-efababbe0b98.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE NeuroVive Pharmaceutical AB (publ) 556595-6538
31 May, 2016
NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes
Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (publ) ("NeuroVive"), as resolved by the Board of Directors on 28 February 2016 and approved by the extraordinary general meeting on 31 March 2016, the number of shares and votes of NeuroVive registered with the Swedish Companies Registration Office have increased by 17,984,960. Accordingly, the total number of shares and votes in NeuroVive is 49,458,645.
About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive's portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive's shares are listed on Nasdaq, Stockholm, Sweden.
For investor relations and media questions, please contact: Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or [email protected]
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 [email protected], www.neurovive.com
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 31 May 2016, at 08.45 CET.